

1 **Differing mechanisms of atrial fibrillation in athletes and non-athletes: alterations in atrial**  
2 **structure and function**

3

4 **Data from large cohort of endurance athletes**

5

6 Siddharth J. Trivedi, BSc, BMedSci (Hons), MBBS (Hons),<sup>a,b</sup> Guido Claessen, MD, PhD,<sup>c,d,e</sup> Luke  
7 Stefani, BBioMedSci (Hons),<sup>a</sup> M. Darragh Flannery, MBBS,<sup>c,f</sup> Paula Brown, PGDipMU,<sup>a</sup> Kristel  
8 Janssens, RN,<sup>c</sup> Adrian Elliott, PhD,<sup>h,i</sup> Prashanthan Sanders, MBBS, PhD,<sup>h,i</sup> Jonathan Kalman,  
9 PhD,<sup>f,j</sup> Hein Heidbuchel, MD, PhD,<sup>k</sup> Liza Thomas, MBBS, PhD,<sup>a,b,l,\*</sup> Andre La Gerche, MD,  
10 PhD,<sup>c,d,f,g,\*</sup>

11

12 <sup>a</sup> Department of Cardiology, Westmead Hospital, Sydney, Australia

13 <sup>b</sup> Westmead Clinical School, The University of Sydney, Sydney, Australia

14 <sup>c</sup> Department of Sports Cardiology, Baker Heart and Diabetes Institute, Melbourne, Australia

15 <sup>d</sup> Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium

16 <sup>e</sup> University Hospitals Leuven, Leuven, Belgium

17 <sup>f</sup> Department of Medicine, University of Melbourne, Melbourne, Australia

18 <sup>g</sup> Department of Cardiology, St Vincent's Hospital, Melbourne, Australia

19 <sup>h</sup> Centre for Heart Rhythm Disorders, South Australian Health and Medical Research  
20 Institute, University of Adelaide, Adelaide, Australia

21 <sup>i</sup> Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia

22 <sup>j</sup> Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia

23 <sup>k</sup> Antwerp University Hospital, University of Antwerp, Edegem, Belgium

24 <sup>l</sup> South Western Sydney Clinical School, University of New South Wales, Sydney, Australia

25

26 \* represents equal senior authorship

27

28 **Word count 4992 words**

29

30 **Funding:** The study was funded, in part, by NHMRC Project Grant APP1130353: Atrial  
31 remodelling and risk of arrhythmias in endurance athletes. SJT is supported by the Cardiac  
32 Society of Australia and New Zealand Research Scholarship (RS2/18) and the National Health  
33 and Medical Research Council Postgraduate Scholarship (1168854). GC is supported by the  
34 Frans Van De Werf Fund for Clinical Cardiovascular Research and the Mathilde Horlait-  
35 Dapsens Scholarship. ALG is supported by a National Heart Foundation Future Leader  
36 Fellowship (102206).

37

38 **Conflict of interest:** The authors have no conflicts to disclose.

39

40 **Address for correspondence:**

41 **Associate Professor Andre La Gerche**

42 Clinical Research Domain, Baker Heart and Diabetes Institute

43 75 Commercial Road, Melbourne, VIC 3004

44 Australia

45 Telephone: +61-3-8532 1867

46 Fax: +61-3-8532 1899

47 Email: [andre.lagerche@baker.edu.au](mailto:andre.lagerche@baker.edu.au)

48

49 **ABSTRACT**

50 **Aims:** Atrial fibrillation (AF) is more common in athletes and may be associated with adverse  
51 left atrial (LA) remodelling. We compared LA structure and function in athletes and non-  
52 athletes with and without AF.

53 **Methods and results:** 144 individuals were recruited from 4 groups (each n=36): 1) endurance  
54 athletes with paroxysmal AF, 2) endurance athletes without AF, 3) non-athletes with  
55 paroxysmal AF, 4) non-athletic healthy controls. Detailed echocardiograms were performed.  
56 Athletes had 35% larger LA volumes and 51% larger left ventricular (LV) volumes versus non-  
57 athletes. Non-athletes with AF had increased LA size compared with controls. LA/LV volume  
58 ratios were similar in both athlete groups and non-athlete controls, but LA volumes were  
59 differentially increased in non-athletes with AF. Diastolic function was impaired in non-  
60 athletes with AF versus non-athletes without, while athletes with and without AF had normal  
61 diastolic function. Compared to non-AF athletes, athletes with AF had increased LA minimum  
62 volumes ( $22.6\pm 5.6$  vs  $19.2\pm 6.7$  ml/m<sup>2</sup>, p=0.033), with reduced LA emptying fraction ( $0.49\pm 0.06$   
63 vs  $0.55\pm 0.12$ , p=0.02), and LA expansion index ( $1.0\pm 0.3$  vs  $1.2\pm 0.5$ , p=0.03). LA reservoir and  
64 contractile strain were decreased in athletes and similar to non-athletes with AF.

65 **Conclusions:** Functional associations differed between athletes and non-athletes with AF,  
66 suggesting different pathophysiological mechanisms. Diastolic dysfunction and reduced strain  
67 defined non-athletes with AF. Athletes had low atrial strain and those with AF had enlarged  
68 LA volumes and reduced atrial emptying, but preserved LV diastolic parameters. Thus, AF in  
69 athletes may be triggered by an atrial myopathy from exercise-induced hemodynamic stretch  
70 consequent to increased cardiac output.

71

72 **KEY WORDS**

73 athletes; athlete's heart; atrial fibrillation; left atrium; strain; diastolic function

74 **ABBREVIATIONS**

75 AF = atrial fibrillation

76 BSA = body surface area

77 EDV = end-diastolic volume

78 ESV = end-systolic volume

79 LA = left atrium

80 LA<sub>max</sub> = left atrial maximum volume

81 LA<sub>min</sub> = left atrial minimum volume

82 LV = left ventricular

83 PVI = pulmonary vein isolation

## 84 INTRODUCTION

85 There is evidence of an increased risk of cardiac arrhythmias, particularly atrial fibrillation  
86 (AF), in endurance athletes (1, 2). Data suggests a “U-shaped” relationship between exercise  
87 dose and cardiac outcomes, where higher exercise doses confer overall health benefits, but  
88 are associated with a higher AF risk (1, 2).

89 However, the mechanisms responsible for ‘exercise-induced’ AF remain unclear. An  
90 established risk factor for AF is left atrial (LA) enlargement (3), typically secondary to diastolic  
91 dysfunction and hypertension. In athletes, LA remodelling (enlargement) is a common  
92 physiologic adaptation to endurance training (4), though affecting only a minority. The  
93 relationship between atrial size and AF risk has not been established in athletes. In this study,  
94 we investigated whether changes in atrial structure and function could differentiate between  
95 athletes with and without AF. Additionally, comparisons were performed with non-athletic  
96 individuals with and without AF, to unravel the pathophysiological mechanisms underpinning  
97 the development of AF with exercise training. We hypothesized that, relative to non-athletes,  
98 there would be significant atrial remodelling in athletes, with greater differences evident in  
99 athletes with AF.

100 **METHODS**

101 *Study population*

102 Thirty six endurance athletes with paroxysmal AF were identified from the ProAFHeart trial,  
103 a prospective multicentre study initiated in 2017 (ACTRN12618000711213), comprising of  
104 former elite rowers and endurance athletes with AF, meeting the following criteria: 1)  
105 previous or current competition in endurance sport (distance running, road or mountain  
106 cycling, rowing or triathlon) at a national or international level, 2) training for endurance  
107 competition for at least 5 years, and 3) no other cardiovascular disease or symptoms. From a  
108 cohort of 249 elite endurance athletes, 47 athletes were identified with at least 1 documented  
109 AF episode requiring medical intervention; of these, 9 were excluded because of chronic AF,  
110 one for hypertrophic cardiomyopathy and another for moderate aortic stenosis. Each athlete  
111 with AF was age- and gender-matched (+/- 5 years) to an athlete in the ProAFHeart trial  
112 without a history of AF (including an exercise test and 72-hour Holter monitor), and any other  
113 cardiac abnormalities.

114 Non-athletic individuals were fit and active but did not participate in competition (i.e. only  
115 recreational sports) and were not engaged in any kind of routine training program. Non-  
116 athletes with AF were recruited from cardiology outpatient clinics, and healthy controls were  
117 recruited from hospital volunteers. Written informed consent was obtained from all subjects  
118 and the study protocol was approved by the Western Sydney Local Health District Human  
119 Research Ethics Committee and the Baker Heart and Diabetes Institute Ethics Committee.

120 There were 144 individuals across 4 groups (n=36 in each): 1) endurance athletes with  
121 paroxysmal AF, 2) endurance athletes without AF, 3) non-athletes with paroxysmal AF, and 4)  
122 non-athletic healthy controls.

123 *Standard Echocardiographic assessment*

124 A comprehensive transthoracic echocardiogram was performed using commercially available  
125 ultrasound machines (Vivid E95, GE Healthcare, Chicago, Illinois) by experienced medical  
126 professionals or cardiac sonographers, blinded to patient information. With patients in left-  
127 lateral decubitus position, parasternal, apical and subcostal images were obtained. Two-  
128 dimensional (2D), colour and Doppler images were obtained; 3-5 consecutive cardiac cycles  
129 were saved in cine format. Measurements were obtained according to the American Society  
130 of Echocardiography recommendations (5) with offline analysis performed using dedicated  
131 software (EchoPac 113, General Electric-Vingmed).

132 LA maximal volume ( $LA_{max}$ ) was measured at end-systole (5) and LA minimum volume ( $LA_{min}$ )  
133 end-diastole by modified Simpson's biplane method of discs from the apical 4- and 2-chamber  
134 views. An average of 3 values was obtained and indexed to body surface area (BSA).

135 LA stroke volume was calculated as  $LA_{max}$  volume -  $LA_{min}$  volume. LA emptying fraction was  
136 calculated as  $(LA_{max} - LA_{min} / LA_{max}) \times 100$ . LA expansion index was calculated as  $(LA_{max} - LA_{min}$   
137  $/ LA_{min}) \times 100$ . All atrial volumes were indexed to BSA.

138 LV mass, LV end-diastolic volume (EDV), LV end-systolic volume (ESV), and LV stroke volume  
139 were calculated and indexed to BSA as recommended (5). Biplane LVEF was also calculated.

140 The ratio of  $LA_{max}$  volume to LVEDV (LA/LV ratio) was assessed to verify whether atrial  
141 remodelling was disproportionate to LV remodelling.

142 Pulsed-wave Doppler mitral inflow velocities were obtained to assess LV diastolic filling, as  
143 recommended (6), including peak E-wave and A-wave, and the E/A ratio.

144 Pulsed tissue Doppler imaging was performed and septal and lateral annular peak systolic ( $s'$ ),  
145 early diastolic ( $e'$ ), and late diastolic ( $a'$ ) annular velocities were obtained (6). The  $E/e'$  was  
146 calculated using an average of septal and lateral  $e'$  (6).

#### 147 *Two-dimensional strain echocardiography*

148 LV and LA strain measurements were obtained from 2-dimensional images (acquired at  $>60$   
149 fps) using software permitting semiautomated analysis (EchoPac version BT 13, General  
150 Electric, Horton Norway) (7). In brief, LA endocardial borders were manually traced in 4- and  
151 2-chamber views. After adjustment of the tracked area and reducing the region of interest for  
152 the thin walled LA, the software divided the atrium into 6 segments (Fig. 1); the tracking  
153 quality for each segment was automatically scored, with the possibility for further manual  
154 correction. Peak atrial reservoir and contractile strain were obtained using R-R wave gating.  
155 Right atrial strain was measured in a similar manner, with strain measurements limited to 6  
156 segments from the apical 4 chamber view.

157 LV global longitudinal strain (GLS) was calculated as the average longitudinal strain from 18  
158 segments obtained from apical 4-, 2-, and 3-chamber view, with the software automatically  
159 subdividing each LV wall into three segments (basal, mid, apical). Peak LV systolic strain was  
160 defined as the peak negative strain during systole.

#### 161 *LA stiffness estimation*

162 LA stiffness was assessed as  $E/e'/$ LA reservoir strain as previously described (8).

#### 163 *Statistical analysis*

164 Analyses were performed using IBM SPSS version 25 (IBM Inc., New York, NY). Continuous  
165 variables are summarized using mean  $\pm$  standard deviation (SD), and categorical variables

166 using frequencies and percentages. Plots of the mean and its associated 95% confidence  
167 interval (CI) by AF status (present vs. absent) and athletic status (athlete vs. non-athlete)  
168 illustrate the distributions of parameters of interest. Two-tailed tests with a significance level  
169 of 5% were used. Repeated measures analysis of variance was used to test for an interaction  
170 between the effect of AF status (present vs. absent) and athletic status (athlete vs. non-  
171 athlete), accounting for matching. A statistically significant interaction signified that the  
172 difference in a parameter measurement in athletes due to AF status differed significantly from  
173 that seen in non-athletes. Independent-samples t tests were used to test for differences by  
174 AF status within athletes and non-athletes, as well as between athletes and non-athletes.

175 **RESULTS**

176 **Baseline characteristics**

177 Demographic characteristics of the study population are presented in Table 1.

178 **Non-athletes**

179 Non-athletes with AF had higher BMI than those without AF (mean difference 2.4kg/m<sup>2</sup>, 95%  
180 CI 0.4-4.4kg/m<sup>2</sup>, p=0.018). Non-athletes with AF had higher heart rates compared to non-  
181 athletes without AF (mean difference 3.9bpm, 95% CI 0.2-7.6bpm, p=0.04).

182 **Athletes**

183 BMI was comparable in athletes with and without AF. Heart rates in athletes were lower than  
184 in non-athletes, with no difference between those with and without AF. Amongst individuals  
185 with AF, the proportion of non-athletes on antiarrhythmic therapy was higher than in  
186 athletes. Only 1 athlete without AF was on a beta blocker for hypertension.

187 **LA parameters**

188 Table 2 summarizes the LA parameters and the effect of AF status within non-athletes and  
189 athletes. The difference in echocardiographic variables by AF status is presented separately  
190 for athletes and non-athletes and reports the p value for interaction.

191 Overall, in both athlete and non-athlete groups, those with AF had greater LA<sub>min</sub> compared to  
192 those without AF (Fig. 2). LA stiffness was reduced in athletes compared to non-athletes.

193 **Non-athletes**

194 Within the non-athletic cohort, LA stiffness was ~~lower in those without~~ increased in those with  
195 AF (Fig. 3).

196 *Athletes*

197 Athletes with AF had significantly lower LA emptying fraction and LA expansion index  
198 compared to athletes without AF (Fig. 2). Athletes with and without AF had similar LA  
199 stiffness.

200 *LA strain*

201 All athletes, as well as non-athletes with AF had reduced LA reservoir (Fig. 4) and contractile  
202 strain compared to non-athletes without AF. The ratio of LA contractile strain (measured in  
203 end-diastole) to LA<sub>min</sub> was significantly lower in both athletes and non-athletes with AF  
204 compared to their matched non-AF controls (Fig. 4).

205 *LV parameters*

206 Table 3 summarizes LV parameters and the effect of AF status within non-athletes and  
207 athletes. All athletes had larger LVEDV compared to non-athletes (Fig. 5). In both non-athlete  
208 and athlete groups, those with AF had larger LVEDV with a trend towards significance. The  
209 LA/LV ratio, as a measure of disproportionate LA-to-LV remodelling, was increased in non-  
210 athletes with AF, but was similar between controls and both athlete groups (Fig. 5). Non-  
211 athletes with AF had greater LV mass, and diastolic parameters including E/e' (Fig. 5) were  
212 significantly impaired, compared to non-athletes without AF. In contrast, both athlete groups  
213 had normal diastolic function.

214 As detailed in Table 3, there was no difference in any of the measured LV parameters between  
215 athletes with and without AF. Overall, LV GLS was lower in athletes compared to non-athletes  
216 (P<0.001).

217 **DISCUSSION**

218 This cross-sectional cohort study, with an age and gender matched comparator population  
219 for endurance athletes, highlights potential differences in LA structural and functional  
220 characteristics between athletes and non-athletes, thereby suggesting different causative  
221 mechanisms for the development of AF. The key findings of our study are that athletes,  
222 including those with AF, have normal diastolic parameters, with atrial enlargement  
223 proportional to LV remodelling. However, athletes with AF have altered atrial function  
224 relative to athletes without AF. In contrast, AF in non-athletes is associated with diastolic  
225 dysfunction and disproportional atrial enlargement.

226 *LA size and function*

227 ~~Endurance training results in~~ As a consequence of repeated, acute hemodynamic alterations  
228 with increased cardiac output ~~endurance training results in,~~ with chronic adaptive changes  
229 in cardiac structure and function (4). All 4 cardiac chambers increase in volume and mass,  
230 the extent of which is proportional to the level of fitness (9). There is recent interest in the  
231 LA and the right ventricle (RV) due to their thin-walled structure and disproportionate  
232 increase in wall stress during exercise (10, 11). Perhaps as a consequence, these chambers  
233 appear to be a common origin of arrhythmias in athletes (12, 13). LA enlargement is an  
234 established risk factor for the development of AF in non-athletes (14), ~~whereas~~ but at the  
235 same time LA enlargement is common even in healthy athletes. Although atrial enlargement  
236 is associated with AF in the general population, its contribution to AF development in  
237 athletes has yet to be determined. Consistent with expectations, we observed increased LA  
238 volumes (both LA<sub>min</sub> and LA<sub>max</sub>) in athletes as compared with healthy non-athletes. The  
239 LA/LV ratio provides a particularly useful index because it expresses LA remodelling relative

240 to LV remodelling. Consistent with descriptions of athletic cardiac remodelling (4), we  
241 observed symmetrical enlargement of all 4 cardiac chambers. As a result, even though atrial  
242 volumes in athletes were greater than healthy non-athletes, the LA/LV ratio was similar.  
243 However, athletes with AF had a similar LA/LV ratio to athletes without AF, whereas non-  
244 athletes with AF had disproportionately enlarged atria (greater LA/LV ratio), probably due to  
245 raised LV pressures. We speculate that the lack of an increase in the LA/LV ratio in athletes  
246 with AF may be due to the lack of LV diastolic impairment. Moreover, it is likely that the  
247 effects of exercise-induced LA remodelling are relatively profound and 'dilute' any  
248 additional remodelling due to AF.

249 It was notable that  $LA_{min}$  was greater in endurance athletes with AF than in athletes with no  
250 AF.  $LA_{min}$ , measured in end-diastole, occurs when the LA is directly exposed to the LV end-  
251 diastolic pressure and is a more sensitive surrogate for LA dysfunction than  $LA_{max}$  (15). In  
252 non-athletic populations  $LA_{min}$  has been demonstrated to be a sensitive marker of LV  
253 diastolic dysfunction that is closely related to the  $E/e'$  ratio and a stronger prognostic  
254 indicator of adverse outcomes than  $LA_{max}$  (16). However, this does not readily explain the  
255 predisposition to AF in endurance athletes, given that LV diastolic function parameters were  
256 similar in athletes with and without AF as well as healthy controls. Hence, there is likely an  
257 associated atrial myopathy in some endurance athletes.

258 Moreover, the development of AF may be multifactorial, including the development of atrial  
259 fibrosis, autonomic imbalance and increased ectopic trigger activity. Thus, while an increase  
260 in  $LA_{max}$  in athletes represents the adaptive change to the increase in stroke volume from  
261 exercise, the increase in  $LA_{min}$  may be a marker of reduced atrial contractility and reflect an  
262 'atrial myopathy'. This would also align with previous observations of prolonged p-wave

263 duration on the ECG of athletes with AF that has been postulated to be an electrical marker  
264 of atrial dysfunction (17).

### 265 *Relative atrial remodelling*

266 The key novel finding in this study is the between group differences in LA/LV ratio. This  
267 simple ratio expresses differential LA remodelling. If atrial size is considered in isolation,  
268 ~~then~~ one might expect an even greater incidence of AF in endurance athlete populations;  
269 however, larger atrial volumes were observed in athletes without AF than in non-athletes  
270 with AF. The corollary is not directly addressed in this study, but it stands to reason that an  
271 increased LA/LV ratio may also be associated with AF in subjects with small stiff ventricles,  
272 whereby even mild increase in atrial volume would represent significant enlargement.

273 LA stiffness is a relatively novel echocardiographic parameter. Filling pressure estimates  
274 ( $E/e'$ ) and myocardial deformation (LA reservoir strain) are combined and have been  
275 validated against invasively measured LA stiffness (8, 18). LA stiffness predicts maintenance  
276 of sinus rhythm after cardioversion for AF (19), and predicts AF recurrences after pulmonary  
277 vein isolation (PVI) (8). In the context of physiological remodelling, the assessment of LA  
278 stiffness in athletes has clarified exercise-induced atrial adaptation, demonstrating that,  
279 despite a greater LA size, remodelling is accompanied by low LA stiffness (20), contrary to  
280 that found in patients with cardiomyopathies or AF. This suggests preserved compliance of  
281 the LA despite increased atrial size, which is primarily mediated via the increased stroke  
282 volume by exercise. The increased LA stiffness in non-athletes with AF would highlight that  
283 the alterations in the LA are a consequence of both LA remodelling as well as functional  
284 reduction in LA compliance.

### 285 *Strain parameters*

286 We observed a lower LV GLS in athletes compared to non-athletes. It is possible that, as a  
287 result of increased LV volume due to athletic remodelling, reduced myocardial deformation  
288 is required to obtain the same stroke volume; hence reduced LV GLS in athletes defines an  
289 adaptive change rather than subclinical myocardial dysfunction. This observation of reduced  
290 GLS in athletes is consistent with a recent study of Dores et al. who observed a high  
291 prevalence of reduced GLS in athletes that was more common in those who were elite, had  
292 a higher volume of training and had greater ventricular and atrial volumes (21). In a similar  
293 manner in the RV, we have demonstrated reduced resting RV deformation in endurance  
294 athletes but normal RV contractile reserve during exercise, suggesting that lower RV  
295 deformation at rest may reflect physiological remodelling and chamber enlargement (22).  
296 Certainly, this observation of reduced LV GLS in athletes warrants further assessment.  
297 Indeed, recent meta-analyses and systematic reviews of athletes in different sports have  
298 shown marked heterogeneity in results, demonstrating greater, similar or even reduced GLS  
299 relative to non-athletic controls (23-25).

300 In our study, LA reservoir and contractile strain were both reduced in athletes as well as  
301 non-athletes with AF. A recent meta-analysis (403 athletes and 297 controls) found that LA  
302 reservoir strain was generally reduced in athletes (26). The larger LA volumes in athletes  
303 implies that they require less deformation at rest to eject similar volumes and it is also  
304 possible that athletes have the ability to augment strain to a greater extent during exercise  
305 (27). However, this potential benefit to atrial performance is obtained at the cost of higher  
306 wall stress (28) that could potentially be a trigger for inducing atrial fibrosis, a known risk  
307 factor for development of AF (29). Reduced LA reservoir strain in non-athletic populations  
308 has been shown to be a strong predictor of AF occurrence (30). A reduction in LA contractile  
309 function is also associated with increased risk of AF (31). Whether these changes in athletes

310 are only benign adaptations to intensive training or represent areas of significant LA  
311 structural alterations that are potential substrates for AF needs to be explored further.

312 Within athletes, we did not identify any differences in LA strain parameters in those with or  
313 without AF. To the best of our knowledge, there is only one previous study by Hubert et al  
314 that has evaluated LA strain in athletes with regards to AF (32). Twenty-seven male  
315 endurance veteran athletes with AF were compared with 30 control endurance athletes  
316 without AF, with similar training level, age, and risk factors. The authors concluded that  
317 veteran male endurance athletes with AF had impaired LA reservoir strain compared to  
318 those without AF. However, there are some differences in our study, with younger  
319 participants enrolled with more stringent endurance training criteria. Our study also  
320 demonstrated increased LA and LV volumes in athletes. It is possible that athletes in the  
321 study by Hubert et al were at earlier stages of athletic remodelling compared to athletes in  
322 our study. The impaired LA strain in AF athletes at earlier stages of remodelling may  
323 represent stretch-induced alterations in myocardial deformation. With increasing intensity  
324 and duration of athletic training, as in our study, athletes likely undergo greater “athletic”  
325 remodelling, possibly nullifying the effects of AF on myocardial deformation. This may  
326 suggest that the definition of an endurance athlete or the degree of athletic remodelling  
327 may play a significant role in modulating the effects of AF on LA function in athletes.

### 328 *Possible mechanisms of AF in athletes*

329 A study of LA structural and functional remodelling in athletes provides important  
330 mechanistic insights of the group in which AF is more prevalent. Our study demonstrates  
331 that atrial dilation occurs in athletes, proportional to the LV and is consequent to the  
332 demands of an increased cardiac output; however, unlike AF in non-athletic populations, is

333 independent of diastolic dysfunction and atrial stiffening. However, we observed several  
334 measures of atrial contractile function that are impaired in both athletic and non-athletic  
335 subjects with AF. Thus, we conclude that atrial contractile dysfunction is an endpoint  
336 associated with AF that is mediated by impaired diastolic relaxation in non-athletes but not  
337 in athletes. We speculate that in athletes, a co-existent atrial myopathy may be a  
338 consequence of frequent exposure to elevated atrial wall stress during exercise (Graphical  
339 Abstract). Although these two differing mechanisms in athletes and non-athletes likely  
340 contribute to LA remodelling and fibrosis in distinct ways, the final consequence in both  
341 scenarios appears to be clinically similar. It is intriguing to speculate that the different  
342 remodelling mechanisms may manifest as different effects on atrial electrophysiology.  
343 However, we are yet to identify many differences in the clinical behaviour of AF in athletes  
344 and the initial experience suggests that PVI is similarly efficacious in athletic and non-  
345 athletic populations (33-35).

346 **STUDY LIMITATIONS**

347 Most of our participants were males and given the increasing involvement of females in  
348 endurance sports, additional studies are required in female athletes. Athletes were selected  
349 from a single centre, and future multicentre studies would be valuable to validate the current  
350 findings. AF athletes and non-athletes had paroxysmal AF, and hence were at an earlier stage  
351 of AF pathogenesis. This attenuated changes in LA remodelling and function due to the AF  
352 itself. Further studies in athletes and non-athletes with more advanced forms of the disease,  
353 such as persistent AF, may provide further insight into progressive LA remodelling.  
354 Furthermore, a longitudinal study is required to determine if the markers associated with AF  
355 in this study can predict athletes at risk of developing AF. Finally, a greater percentage of  
356 individuals with AF were on antiarrhythmic medications (both athletes and non-athletes) in  
357 our study. We accept that medication use can affect LA and LV function; however, after  
358 excluding individuals on medications, our small sample size did not allow performing a  
359 sensitivity analysis to assess this further.

360 **CONCLUSIONS**

361 This cross-sectional study highlights mechanistic and functional differences in athletes and  
362 non-athletes with AF, suggesting distinct pathophysiological mechanisms. Diastolic  
363 dysfunction, atrial dilation and reduced LA strain defined non-athletes with AF. In athletes,  
364 atrial enlargement and reduced atrial strain ~~was~~were universal with only subtle further  
365 changes in those with AF. It is therefore important to recognise that atrial measures  
366 considered abnormal in the general population are common in athletes. Despite this,  
367 differences in atrial contractile function are appreciable in athletes with AF and raise the  
368 possibility that endurance training can promote an atrial myopathy in a subset of athletes as  
369 ~~distinct~~opposed to~~from~~ the non-athletic population where diastolic dysfunction appears to  
370 be the key driver for AF.

371

372 **REFERENCES**

- 373 1. Gerche AL, Schmied CM. Atrial fibrillation in athletes and the interplay between  
374 exercise and health. *Eur Heart J.* 2013;34(47):3599-602.
- 375 2. Flannery MD, Kalman JM, Sanders P, La Gerche A. State of the Art Review: Atrial  
376 Fibrillation in Athletes. *Heart Lung Circ.* 2017;26(9):983-9.
- 377 3. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of  
378 nonrheumatic atrial fibrillation. The Framingham Heart Study. *Circulation.* 1994;89(2):724-30.
- 379 4. Prior DL, La Gerche A. The athlete's heart. *Heart.* 2012;98(12):947-55.
- 380 5. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.  
381 Recommendations for cardiac chamber quantification by echocardiography in adults: an  
382 update from the American Society of Echocardiography and the European Association of  
383 Cardiovascular Imaging. *European heart journal cardiovascular Imaging.* 2015;16(3):233-70.
- 384 6. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al.  
385 Recommendations for the Evaluation of Left Ventricular Diastolic Function by  
386 Echocardiography: An Update from the American Society of Echocardiography and the  
387 European Association of Cardiovascular Imaging. *European heart journal cardiovascular*  
388 *Imaging.* 2016;17(12):1321-60.
- 389 7. D'Ascenzi F, Pelliccia A, Natali BM, Zaca V, Cameli M, Alvino F, et al. Morphological and  
390 functional adaptation of left and right atria induced by training in highly trained female  
391 athletes. *Circ Cardiovasc Imaging.* 2014;7(2):222-9.
- 392 8. Machino-Ohtsuka T, Seo Y, Tada H, Ishizu T, Machino T, Yamasaki H, et al. Left atrial  
393 stiffness relates to left ventricular diastolic dysfunction and recurrence after pulmonary vein  
394 isolation for atrial fibrillation. *J Cardiovasc Electrophysiol.* 2011;22(9):999-1006.

- 395 9. Steding K, Engblom H, Buhre T, Carlsson M, Mosen H, Wohlfart B, et al. Relation  
396 between cardiac dimensions and peak oxygen uptake. *J Cardiovasc Magn Reson.* 2010;12:8.
- 397 10. La Gerche A, Heidbuchel H, Burns AT, Mooney DJ, Taylor AJ, Pflugger HB, et al.  
398 Disproportionate exercise load and remodeling of the athlete's right ventricle. *Med Sci Sports*  
399 *Exerc.* 2011;43(6):974-81.
- 400 11. La Gerche A, Burns AT, Mooney DJ, Inder WJ, Taylor AJ, Bogaert J, et al. Exercise-  
401 induced right ventricular dysfunction and structural remodelling in endurance athletes. *Eur*  
402 *Heart J.* 2012;33(8):998-1006.
- 403 12. Gerche AL, Heidbuchel H. Can Intensive Exercise Harm the Heart? *Circulation.*  
404 2014;130(12):992-1002.
- 405 13. La Gerche A, Claessen G, Dymarkowski S, Voigt JU, De Buck F, Vanhees L, et al.  
406 Exercise-induced right ventricular dysfunction is associated with ventricular arrhythmias in  
407 endurance athletes. *Eur Heart J.* 2015;36(30):1998-2010.
- 408 14. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, et al. Left  
409 atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and  
410 women. *Mayo Clin Proc.* 2001;76(5):467-75.
- 411 15. Caselli S, Canali E, Foschi ML, Santini D, Di Angelantonio E, Pandian NG, et al. Long-  
412 term prognostic significance of three-dimensional echocardiographic parameters of the left  
413 ventricle and left atrium. *European Journal of Echocardiography.* 2010;11(3):250-6.
- 414 16. Prasad SB, Guppy-Coles K, Stanton T, Armstrong J, Krishnaswamy R, Whalley G, et al.  
415 Relation of Left Atrial Volumes in Patients With Myocardial Infarction to Left Ventricular Filling  
416 Pressures and Outcomes. *The American journal of cardiology.* 2019;124(3):325-33.

- 417 17. Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid J-P, Saner H. Atrial remodeling,  
418 autonomic tone, and lifetime training hours in nonelite athletes. *The American journal of*  
419 *cardiology*. 2011;108(4):580-5.
- 420 18. Kurt M, Wang J, Torre-Amione G, Nagueh SF. Left atrial function in diastolic heart  
421 failure. 2009;1(1):10-5.
- 422 19. Shaikh AY, Maan A, Khan UA, Aurigemma GP, Hill JC, Kane JL, et al. Speckle  
423 echocardiographic left atrial strain and stiffness index as predictors of maintenance of sinus  
424 rhythm after cardioversion for atrial fibrillation: a prospective study. *Cardiovasc*. 2012;10:48.
- 425 20. D'Ascenzi F, Pelliccia A, Natali BM, Cameli M, Andrei V, Incampo E, et al. Increased left  
426 atrial size is associated with reduced atrial stiffness and preserved reservoir function in  
427 athlete's heart. *The international journal of cardiovascular imaging*. 2015;31(4):699-705.
- 428 21. Dores H, Mendes L, Dinis P, Cardim N, Monge JC, Santos JF. Myocardial deformation  
429 and volume of exercise: a new overlap between pathology and athlete's heart? *The*  
430 *international journal of cardiovascular imaging*. 2018;34(12):1869-75.
- 431 22. La Gerche A, Burns AT, D'Hooge J, Maclsaac AI, Heidbüchel H, Prior DL. Exercise Strain  
432 Rate Imaging Demonstrates Normal Right Ventricular Contractile Reserve and Clarifies  
433 Ambiguous Resting Measures in Endurance Athletes. *Journal of the American Society of*  
434 *Echocardiography*. 2012;25(3):253-62.e1.
- 435 23. Beaumont A, Grace F, Richards J, Hough J, Oxborough D, Sculthorpe N. Left ventricular  
436 speckle tracking-derived cardiac strain and cardiac twist mechanics in athletes: a systematic  
437 review and meta-analysis of controlled studies. *Sports Medicine*. 2017;47(6):1145-70.
- 438 24. D'Ascenzi F, Caselli S, Solari M, Pelliccia A, Cameli M, Focardi M, et al. Novel  
439 echocardiographic techniques for the evaluation of athletes' heart: A focus on speckle-  
440 tracking echocardiography. *European journal of preventive cardiology*. 2016;23(4):437-46.

- 441 25. La Gerche A, Taylor AJ, Prior DL. Athlete's heart: the potential for multimodality  
442 imaging to address the critical remaining questions. *JACC: Cardiovascular Imaging*.  
443 2009;2(3):350-63.
- 444 26. Cuspidi C, Tadic M, Sala C, Gherbesi E, Grassi G, Mancia G. Left atrial function in elite  
445 athletes: a meta-analysis of two-dimensional speckle tracking echocardiographic studies.  
446 *Clinical cardiology*. 2019;42(5):579-87.
- 447 27. Sanchis L, Sanz-de La Garza M, Bijmens B, Giraldeau G, Grazioli G, Marin J, et al. Gender  
448 influence on the adaptation of atrial performance to training. *European journal of sport  
449 science*. 2017;17(6):720-6.
- 450 28. Gabrielli L, Bijmens BH, Butakoff C, Duchateau N, Montserrat S, Merino B, et al. Atrial  
451 functional and geometrical remodeling in highly trained male athletes: for better or worse?  
452 *European journal of applied physiology*. 2014;114(6):1143-52.
- 453 29. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association  
454 of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter  
455 ablation: the DECAAF study. *Jama*. 2014;311(5):498-506.
- 456 30. Mirza M, Caracciolo G, Khan U, Mori N, Saha SK, Srivathsan K, et al. Left atrial reservoir  
457 function predicts atrial fibrillation recurrence after catheter ablation: a two-dimensional  
458 speckle strain study. *Journal of interventional cardiac electrophysiology*. 2011;31(3):197-206.
- 459 31. Negishi K, Negishi T, Zardkoohi O, Ching EA, Basu N, Wilkoff BL, et al. Left atrial booster  
460 pump function is an independent predictor of subsequent life-threatening ventricular  
461 arrhythmias in non-ischaemic cardiomyopathy. *European Heart Journal-Cardiovascular  
462 Imaging*. 2016;17(10):1153-60.

- 463 32. Hubert A, Galand V, Donal E, Pavin D, Galli E, Martins RP, et al. Atrial function is altered  
464 in lone paroxysmal atrial fibrillation in male endurance veteran athletes. *Eur Heart J*  
465 *Cardiovasc Imaging*. 2018;19(2):145-53.
- 466 33. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L, et al. Efficacy  
467 of radiofrequency catheter ablation in athletes with atrial fibrillation. *EP Europace*.  
468 2011;13(10):1386-93.
- 469 34. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, et al. Efficacy of  
470 circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes.  
471 *Europace*.12(1):30-6.
- 472 35. Decroocq M, Ninni S, Klein C, Machuron F, Verbrugge E, Klug D, et al. No impact of  
473 sports practice before or after atrial fibrillation ablation on procedure efficacy in athletes: a  
474 case-control study. *Europace*. 2019.

475 **FIGURE TITLES AND LEGENDS**

476 **Fig. 1. Left atrial strain measurement (apical 4 chamber view) from 6 segments (different**  
477 **colours), with corresponding strain curves, and average strain curve (dotted line).**

478 **Abbreviations:** LA = left atrial

479 **Fig. 2. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
480 **status (athlete vs. non-athlete) for indexed LA minimum and maximum volume, LA**  
481 **emptying fraction, and LA expansion index. Abbreviations:** AF = atrial fibrillation; LA = left  
482 atrial

483 **Fig. 3. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
484 **status (athlete vs. non-athlete) for LA stiffness and E/e'. Abbreviations:** AF = atrial  
485 fibrillation; LA = left atrial


486 **Fig. 4. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
487 **status (athlete vs. non-athlete) for LA reservoir strain and ratio of LA contractile strain/LA**  
488 **minimum volume indexed. Abbreviations:** AF = atrial fibrillation; LA = left atrial; LA min vol  
489 = left atrial minimum volume indexed

490 **Fig. 5. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
491 **status (athlete vs. non-athlete) for LV end diastolic volume indexed, and ratio of indexed**  
492 **LA/LV volume. Abbreviations:** AF = atrial fibrillation; EDV = end diastolic volume; LA = left  
493 atrial; LV = left ventricular

494 **GRAPHICAL ABSTRACT. Mechanisms of atrial fibrillation in athletes and non-athletes**


495

496 **Figure 1. Left atrial strain measurement (apical 4 chamber view) from 6 segments**  
497 **(different colours), with corresponding strain curves, and average strain curve (dotted**  
498 **line)**




500 **Abbreviations:** LA = left atrial

501 **Figure 2. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
 502 **status (athlete vs. non-athlete) for indexed LA minimum and maximum volume, LA**  
 503 **emptying fraction, and LA expansion index**



505 **Abbreviations:** AF = atrial fibrillation; LA = left atrial


506 **Figure 3. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
 507 **status (athlete vs. non-athlete) for LA stiffness and E/e'**



508

509 **Abbreviations:** AF = atrial fibrillation; LA = left atrial

510 **Figure 4. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
 511 **status (athlete vs. non-athlete) for LA reservoir strain and ratio of LA contractile strain/LA**  
 512 **minimum volume indexed**




513

514 **Abbreviations:** AF = atrial fibrillation; LA = left atrial; LA min vol = left atrial minimum


515 volume indexed

516 **Figure 5. Mean and 95% confidence interval by AF status (present vs. absent) and athletic**  
 517 **status (athlete vs. non-athlete) for LV end diastolic volume indexed, and ratio of indexed**  
 518 **LA/LV volume**



519

520 **Abbreviations:** AF = atrial fibrillation; EDV = end diastolic volume; LA = left atrial; LV = left  
 521 ventricular



526 Table 1. Baseline characteristics of the study population

Variable	Non-athletes		Athletes	
	No AF	AF	No AF	AF
Age (years)	55.3 ± 13.5	54.5 ± 13.9	56.4 ± 12.7	56.5 ± 13.2
Males, n (%)	34 (94%)	34 (94%)	34 (94%)	34 (94%)
Height (m)	1.74 ± 0.09	1.75 ± 0.06	1.84 ± 0.08	1.82 ± 0.09
Weight (kg)	80 ± 17	87 ± 12	85 ± 12	82 ± 13
Body mass index (kg/m <sup>2</sup> )	26.0 ± 4.5	28.4 ± 3.7	25.0 ± 2.7	24.7 ± 2.1
Body surface area (m <sup>2</sup> )	1.94 ± 0.2	2.02 ± 0.15	2.07 ± 0.18	2.04 ± 0.20
Heart rate (beats/min)	62 ± 10	68 ± 9	53 ± 8	51 ± 9
Hypertension, n (%)	0.0	10 (28)	3 (8)	5 (14)
SBP (mmHg)	118 ± 11	147 ± 10	130 ± 11	137 ± 23
DBP (mmHg)	76 ± 8	88 ± 9	73 ± 9	73 ± 11
Smoking, n (%)	0.0	0.0	0.0	0.0
Diabetes Mellitus, n (%)	0.0	0.0	0.0	1 (3)
Antiarrhythmic medications				
Beta-blocker, n (%)	0.0	8 (22)	1 (3)	4 (11)
Calcium-channel blocker, n (%)	0.0	4 (11)	0.0	1 (3)
Cardiac glycoside, n (%)	0.0	3 (8)	0.0	0.0
Sotalol, n (%)	0.0	14 (39)	0.0	2 (6)
Flecainide, n (%)	0.0	3 (8)	0.0	3 (8)
Amiodarone, n (%)	0.0	7 (19)	0.0	1 (3)

527

528 Values are mean  $\pm$  SD or n (%).

529 **Abbreviations:** AF = atrial fibrillation; DBP = diastolic blood pressure; SBP = systolic blood

530 pressure

**Table 2. Matched analysis of the effect of AF status within non-athletes and athletes for LA echocardiographic parameters**

Variable	Non-athletes		P value for non- athletes	Athletes		P value for athletes	P value athletes vs non- athletes	P value for interaction between athletic status and AF status
	No AF	AF		No AF	AF			
Minimum LA volume indexed (ml/m <sup>2</sup> )	13.0 ± 4.3	19.9 ± 8.2	<0.001	19.2 ± 6.7	22.6 ± 5.6	0.022	<0.001	0.10
Maximum LA volume indexed (ml/m <sup>2</sup> )	27.3 ± 7.9	37.8 ± 11.2	<0.001	43.2 ± 11.7	44.5 ± 10.7	0.61	<0.001	0.011
LA stroke volume indexed	14.3 ± 5.8	18.0 ± 7.4	0.022	23.9 ± 10.0	21.9 ± 6.6	0.30	<0.001	0.050
LA emptying fraction indexed	0.51 ± 0.19	0.48 ± 0.15	0.53	0.55 ± 0.12	0.49 ± 0.06	0.011	0.30	0.52
LA expansion index indexed	1.2 ± 0.5	1.1 ± 0.6	0.48	1.2 ± 0.5	1.0 ± 0.3	0.009	0.71	0.39
LA stiffness	0.24 ± 0.09	0.37 ± 0.20	0.001	0.22 ± 0.09	0.22 ± 0.07	0.93	<0.001	0.001

LA reservoir strain (%)	33.2 ± 7.1	27.9 ± 8.4	0.005	28.2 ± 3.7	27.2 ± 4.5	0.32	0.008	0.032
LA conduit strain (%)	16.6 ± 6.3	14.9 ± 5.5	0.22	14.4 ± 4.0	14.2 ± 4.5	0.83	0.09	0.26
LA contractile strain (%)	16.6 ± 3.1	13.0 ± 5.1	0.001	13.8 ± 3.6	13.0 ± 3.1	0.32	0.032	0.026
LA contractile strain / LA minimum volume indexed ratio	1.4 ± 0.5	0.9 ± 0.6	<0.001	0.8 ± 0.4	0.6 ± 0.2	0.021	<0.001	0.006

Values are mean ± SD, and mean difference and its 95% CI

**Abbreviations:** AF = atrial fibrillation; DT = deceleration time; EDV = end diastolic volume; ESV = end systolic volume; LA = left atrial; LV = left ventricular

**Table 3. Matched analysis of the effect of AF status within non-athletes and athletes for LV echocardiographic parameters**

Variable	Non-athletes		P value for non-athletes	Athletes		P value for athletes	P value athletes vs non-athletes	P value for interaction between athletic status and AF status
	No AF	AF		No AF	AF			
LVESV indexed (ml/m <sup>2</sup> )	27.0 ± 33.0	25.0 ± 8.0	0.68	34.0 ± 7.0	35.0 ± 6.0	0.50	0.002	0.16
LVEDV indexed (ml/m <sup>2</sup> )	51.4 ± 13.2	56.5 ± 10.2	0.07	78.6 ± 13.9	84.2 ± 12.1	0.08	<0.001	0.90
LV ejection fraction (%)	58.0 ± 8.0	56.0 ± 10.0	0.41	56.0 ± 4.0	58.0 ± 4.0	0.15	0.80	0.10
LV mass indexed (g/m <sup>2</sup> )	78.0 ± 15.0	94.0 ± 27.0	0.003	90.0 ± 19.0	94.0 ± 14.0	0.29	0.11	0.09
Indexed LA/LV ratio	0.24 ± 0.07	0.31 ± 0.12	0.002	0.22 ± 0.06	0.22 ± 0.05	0.58	<0.001	0.002
Peak E (cms <sup>-1</sup> )	66.0 ± 10.0	71.0 ± 19.0	0.13	55.0 ± 12.0	57.0 ± 13.0	0.50	<0.001	0.47

Peak A (cms <sup>-1</sup> )	61.0 ± 15.0	54.0 ± 18.0	0.09	47.0 ± 11.0	48.0 ± 13.0	0.77	<0.001	0.08
E/A	1.2 ± 0.4	1.5 ± 0.7	0.013	1.3 ± 0.5	1.3 ± 0.5	0.90	0.64	0.023
Average e' vel (cms <sup>-1</sup> )	9.0 ± 2.0	8.0 ± 2.0	0.09	10.0 ± 3.0	10.0 ± 2.0	0.49	0.003	0.025
E/e'	7.5 ± 1.9	9.1 ± 3.3	0.011	5.9 ± 1.8	5.7 ± 1.3	0.52	<0.001	0.010
LV GLS (%)	21.7 ± 2.9	21.0 ± 3.1	0.34	18.9 ± 2.1	19.2 ± 1.7	0.58	<0.001	0.20

Values are mean ± SD, and mean difference and its 95% CI

**Abbreviations:** AF = atrial fibrillation; DT = deceleration time; EDV = end diastolic volume; ESV = end systolic volume; LA = left atrial; LV = left ventricular